Physiological "constants" for PBPK models for pregnancy.
Physiologically based pharmacokinetic (PBPK) models for pregnancy are inherently more complex than conventional PBPK models due to the growth of the maternal and embryo/fetal tissues. Physiological parameters such as compartmental volumes or flow rates are relatively constant at any particular time during gestation when an acute experiment might be conducted, but vary greatly throughout the course of gestation (e.g., contrast relative fetal weight during the first month of gestation with the ninth month). Maternal physiological parameters change during gestation, depending upon the particular system; for example, cardiac output increases by approximately 50% during human gestation; plasma protein concentration decreases during pregnancy; overall metabolism remains fairly constant. Maternal compartmental volumes may change by 10-30%; embryo/fetal volume increases over a billionfold from conception to birth. Data describing these physiological changes in the human are available from the literature. Human embryo/fetal growth can be well described using the Gompertz equation. By contrast, very little of these same types of data is available for the laboratory animal. In the rodent there is a dearth of information during organogenesis as to embryo weights, and even less organ or tissue weight or volume data during embryonic or fetal periods. Allometric modeling offers a reasonable choice to extrapolate (approximately) from humans to animals; validation, however, is confined to comparisons with limited data during the late embryonic and fetal periods of development (after gestation d 11 in the rat and mouse). Embryonic weight measurements are limited by the small size of the embryo and the current state of technology. However, the application of the laser scanning confocal microscope (LSCM) to optically section intact embryos offers the capability of precise structural measurements and computer-generated three-dimensional reconstruction of early embryos. Application of these PBPK models of pregnancy in laboratory animal models at teratogenically sensitive periods of development provides exposure values at specific target tissues. These exposures provide fundamentally important data to help design and interpret molecular probe investigations into mechanisms of teratogenesis.
Young
J F
JF
Division of Reproductive and Development Toxicology, National Center for Toxicological Research, Jefferson, Arkansas 72079, USA. JYOUNG@NCTR.FDA.GOV
Branham
W S
WS
Sheehan
D M
DM
Baker
M E
ME
Wosilait
W D
WD
Luecke
R H
RH
D000818:Animals; D004622:Embryo, Mammalian / Q000378:metabolism / Q000502:physiology*; D005260:Female; D005333:Fetus / Q000378:metabolism / Q000502:physiology*; D005865:Gestational Age; D006801:Humans; D008954:Models, Biological; D010599:Pharmacokinetics; D011247:Pregnancy / Q000378:metabolism / Q000502:physiology*; D012377:Rodentia; D013045:Species Specificity